Jefferies Reiterates Buy on Quest Diagnostics, Lifts Price Target to $220

Investment bank Jefferies has reaffirmed its "Buy" rating for Quest Diagnostics (DGX) and increased its price target for the diagnostic testing provider. The target was raised from $215 to $220, signaling continued confidence in the company's prospects. This adjustment reflects positive expectations for Quest Diagnostics' future performance, aligning with a general sentiment of growth within the sector. Other analysts have also recently updated their assessments and price targets for DGX. Such actions from a major investment bank typically serve as a positive signal for the stock, potentially attracting further investor interest.